October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
3 citations
,
July 2025 in “British Journal of Dermatology” Cinainu is effective and safe for treating children's alopecia areata.
14 citations
,
April 2023 in “Acta Dermato Venereologica” Upadacitinib effectively treated severe hair loss in a child.
November 2025 in “Journal of Investigative Dermatology”
25 citations
,
November 2022 in “British journal of dermatology/British journal of dermatology, Supplement” Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
3 citations
,
August 2023 in “Drug safety” Proactive monitoring and management are essential to maximize the benefits of Trastuzumab Deruxtecan while minimizing serious side effects.
9 citations
,
November 2023 in “Supportive Care in Cancer” Minoxidil improves hair loss in breast cancer patients on CDK4/6-inhibitor therapy.
January 2023 in “Applied sciences” Gefitinib and Sasam-Kyeongokgo together significantly reduce cancer growth and improve immune response in mice.
January 2026 in “Nanoscale Advances” The nanocomposite effectively targets lung cancer cells without harming normal cells.
August 2024 in “Dermatology and Therapy” Vorasidenib can cause unusual hair growth.
153 citations
,
January 2001 in “Science” Using CDK inhibitors on rats showed a reduction in chemotherapy-caused hair loss, but later experiments could not repeat these results.
16 citations
,
February 2019 in “Pediatric Blood & Cancer” Most children with CNS tumors on targeted therapy had skin reactions, which were generally treatable without stopping the therapy.
1 citations
,
April 2022 in “F1000Research” Most pediatric cancer patients at Muhimbili National Hospital in Tanzania experienced side effects from chemotherapy, with nausea, hair loss, and low white blood cell count being the most common.
11 citations
,
October 2019 in “Cancers” Spironolactone may make some cancer treatments more effective by blocking a protein that helps cancer cells survive.
14 citations
,
January 2017 in “Pharmacological Reports” TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.
June 1993 in “Current opinion in therapeutic patents” Hexahydrobenzo[f]quinolines are effective at blocking the enzyme 5α-reductase.
8 citations
,
January 2017 in “Dermatology online journal” Tofacitinib helped psoriasis but not alopecia universalis, needing more research.
May 2012 in “Journal of Clinical Oncology” Taking 5-alpha reductase inhibitors might be linked to breast cancer in men.
3 citations
,
November 1998 in “PubMed”
1 citations
,
January 2023 in “Cutis” The paper concludes that the new medication baricitinib needs further testing in a more diverse group of patients with alopecia areata.
September 2017 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking CCR5 can prevent and improve hair loss in alopecia areata.
13 citations
,
June 2008 in “International Journal of Dermatology” Sorafenib can cause a unique skin reaction.
More research is needed to understand chemotherapy-induced hair loss and its phases.
7 citations
,
June 2007 in “AIDS” A man's hair loss was linked to his HIV medication, which improved after changing drugs.
October 2018 in “Annals of oncology” Topical calcitriol (BPM31543) is safe for preventing hair loss from chemotherapy and shows some effectiveness.
1 citations
,
May 2017 in “Journal of Clinical Oncology” Topical calcitriol is safe for preventing hair loss during chemotherapy.
February 2024 in “Frontiers in Cell and Developmental Biology” Eribulin-based chemotherapy is more effective and has fewer side effects for advanced triple-negative breast cancer.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
1 citations
,
October 2019 in “Journal of Thoracic Oncology” Chemotherapy adds to, but doesn't enhance, the effects of immunotherapy in lung cancer treatment.
January 2019 in “프로그램북(구 초록집)” Both tofacitinib and ruxolitinib are effective and tolerable for treating alopecia areata.